METHODS: A cohort of 129 children aged 1-10 years in Kampala, Uganda, were treated with amodiaquine plus sulfadoxine-pyrimethamine for 396 episodes of uncomplicated malaria over a 29-month period as part of a longitudinal clinical trial.
RESULTS: The risk of treatment failure increased over the course of the study from 5% to 21% (hazard ratio [HR] CONCLUSION: Declining immunity in our study population appeared to be the primary factor underlying decreased efficacy of amodiaquine plus sulfadoxinepyrimethamine. With improved malaria-control efforts, decreasing immunity may unmask resistance to partially efficacious drugs.
